Cogent Biosciences, Inc. Share Price & Technical Analysis
COGT · $33.93 (-1.05%)
Healthcare / Biotechnology
$33.93
-1.05%
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well …
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-9% return in May, 12% avg return in past 3 year May month.
-6% return in 2026, 77% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 1% | 6% | 1% | -5% | -9% | – | – | – | – | – | – | – | -6% |
| 25 | 18% | -18% | -21% | -13% | 4% | 24% | 58% | 7% | 21% | 16% | 148% | -10% | 233% |
| 24 | -24% | 59% | -6% | -3% | 23% | 4% | 12% | 13% | 0% | 6% | -18% | -18% | 48% |
| 23 | 30% | -13% | -19% | 1% | 9% | 1% | 10% | -6% | -20% | -15% | -6% | -23% | -51% |
| 22 | -11% | -22% | 27% | -15% | -27% | 96% | 26% | 49% | -9% | -11% | -9% | -8% | 87% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.82B
P/E ratio
—
52W high
$43.73
52W low
$4.55
Volume
5,35,939
Beta
0.37
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Cogent Biosciences, Inc. share price today?
- Cogent Biosciences, Inc. (COGT) last traded around $33.93 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does COGT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for COGT. Download the app for real-time alerts.
- How can I analyze Cogent Biosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.